EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time

Diego Salas-Benito, Filippo Birocchi, Sangwoo Park, Cassidy E Ho, Alexander Armstrong, Aiyana L Parker, Amanda A Bouffard, Jessica A Frank, Eugene Kim, Tamina Kienka, Kiana Graham, Christopher Kelly und 6 weitere

Journal for ImmunoTherapy of Cancer · 2025-09 · 13 (9) · e012822

DOI: 10.1136/jitc-2025-012822 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 09.09.2025. Verfasst von Diego Salas-Benito und 17 weiteren Autor:innen. Beteiligte Einrichtung: Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, T-Lymphocytes, CA-125 Antigen, Membrane Proteins. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS, Nile Albright Research Foundation, American-Italian Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tumor heterogeneity and antigen escape are mechanisms of resistance to chimeric antigen receptor (CAR)-T cell therapy, especially in solid tumors. Targeting multiple antigens with a unique CAR construct could be a strategy for a better tumor control than monospecific CAR-T cells on heterogeneous models. To overcome tumor heterogeneity, we targeted mesothelin (meso) and Mucin 16 (MUC16), two antigens commonly expressed in solid tumors, using a tandem CAR design.

Methods

We designed a series of tandem CAR constructs based on various anti-meso (SS1) and anti-MUC16 ectodomain (MUC16ecto) (4H11) single-chain variable fragment (scFv) arrangements and G4S linker lengths. Then we determined the best tandem CAR design based on binding of soluble antigens, steric hindrance, avidity and functionality against cell lines expressing one or both antigens in vitro. Finally, we compared the tandem CAR to monospecific CAR-T cells in mixed tumor models in vitro (two-dimensional and three-dimensional models) and in vivo.

Results

We show that the scFv arrangement and linker length impacted antigen binding and CAR expression in T cells. Tandem CAR configuration (TanCAR1) (with SS1 scFv located distally and one G4S repeat as the linker between scFvs) had the best binding and activation profile in vitro and outperformed SS1 and 4H11 monospecific CAR-T cells in mixed tumor models in vitro and in vivo, showing an antigen-driven killing of tumor cells based on antigen density. Moreover, acoustic force microscopy, using tumor cells with different levels of antigen expression, revealed that TanCAR1-T cells likely bind to one antigen at a time rather than simultaneously.

Conclusions

This is the first time using a tandem CAR design targeting meso and MUC16, and demonstrating a benefit on tumor control over monospecific CAR-T cells. Tandem CAR-T cells targeting meso and MUC16ecto could be employed as a strategy to overcome tumor cell heterogeneity in ovarian and pancreatic tumors, and may help to design therapeutic approaches relying on its one-antigen-at-a-time binding properties and on its antigen-driven killing of tumor cells based on antigen density.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenT-LymphocytesCA-125 AntigenMembrane ProteinsMesothelinHumansCell Line, TumorImmunotherapy, AdoptiveFemaleAnimalsMiceNeoplasmsT-Lymphocytes, CytotoxicAntigens

Stichwörter der Autor:innen

Chimeric antigen receptor - CARGastrointestinal CancerOvarian Cancer

Substanzen

Receptors, Chimeric AntigenMUC16 protein, humanCA-125 AntigenMembrane ProteinsMesothelinAntigensMSLN protein, humanMsln protein, mouse

Autor:innen und Institutionen

  • Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Program in Immunology, Harvard Medical School, Boston, Massachusetts, USA.
  • Vincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, Massachusetts, USA.

Förderung

  • NIGMS NIH HHS
  • Nile Albright Research Foundation
  • American-Italian Cancer Foundation
  • Vincent Memorial Hospital Foundation
  • CRIS Cancer Foundation
  • Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant
  • NIH
  • Associazione Italiana per la Ricerca sul Cancro

Zitieren

APA

Salas-Benito, D., Birocchi, F., Park, S., Ho, C. E., Armstrong, A., Parker, A. L., Bouffard, A. A., Frank, J. A., Kim, E., Kienka, T., Graham, K., Kelly, C., Goncalves, S., Leick, M. B., Escobar, G., Rueda, B., Berger, T. R., & Maus, M. V. (2025). Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time. Journal for ImmunoTherapy of Cancer, 13(9), e012822. https://doi.org/10.1136/jitc-2025-012822

Vancouver

Salas-Benito D, Birocchi F, Park S, Ho CE, Armstrong A, Parker AL, et al. Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time. Journal for ImmunoTherapy of Cancer. 2025;13(9):e012822. doi:10.1136/jitc-2025-012822

BibTeX
@article{SalasBenito2025,
  author = {Salas-Benito, Diego and Birocchi, Filippo and Park, Sangwoo and Ho, Cassidy E and Armstrong, Alexander and Parker, Aiyana L and Bouffard, Amanda A and Frank, Jessica A and Kim, Eugene and Kienka, Tamina and Graham, Kiana and Kelly, Christopher and Goncalves, Sadie and Leick, Mark B and Escobar, Giulia and Rueda, Bo and Berger, Trisha R and Maus, Marcela V},
  title = {Tandem CAR-T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {9},
  pages = {e012822},
  doi = {10.1136/jitc-2025-012822}
}
Kostenlos starten →